Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.
It was the aim of this work to establish whether biotransformation of drugs by the liver expressed by antipyrine kinetics is disturbed in peritoneally dialysed patients with end-stage renal failure. The investigations were carried out in 10 uraemic patients using the antipyrine test and comparing the parameters of antipyrine kinetics with those obtained in 13 healthy persons. Our results indicate that in uraemic patients on regular peritoneal dialysis treatment antipyrine kinetics are generally in the normal range, suggesting the microsomal content of cytochrome P-450 being not evidently reduced.
Grzegorzewska
A
A
Department of Nephrology, K. Marcinkowki Academy of Medicine, Poznań, Poland.
Lowicki
Z
Z
Chmara
E
E
Mrozikiewicz
A
A
Baczyk
K
K
D000983:Antipyrine / Q000493:pharmacokinetics*; D001711:Biotransformation / Q000502:physiology; D006801:Humans; D008099:Liver / Q000378:metabolism*; D010530:Peritoneal Dialysis; D012016:Reference Values; D014511:Uremia / Q000378:metabolism* / Q000628:therapy
D000983:Antipyrine